A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability and efficacy of orally administered QAL964 in patients with active rheumatoid arthritis on stable doses of methotrexate and with inadequate response to methotrexate

Trial Profile

A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability and efficacy of orally administered QAL964 in patients with active rheumatoid arthritis on stable doses of methotrexate and with inadequate response to methotrexate

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 May 2015

At a glance

  • Drugs QAL 964 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 16 May 2015 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 15 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top